Alphamab Oncology announced in its annual report ending December 31, 2023, focuses on bi-specific antibody and protein engineering with the aim of promoting innovative biopharmaceuticals globally. The product pipeline includes tumor monoclonal antibodies, binospecific antibodies, and ADCs, of which one product has been approved and the other three are in the post-clinical stage. The company's first commercialized product is KN035 (Envafolimab), but commercialization experience is limited. The financial summary showed that total revenue reached RMB218.8 million, an increase over the previous year, with a net loss of RMB210.6 million, a decrease in the loss margin compared to last year. DURING THE REPORTING PERIOD, THE COMPANY DID NOT PROPOSE TO DISTRIBUTE DIVIDENDS AND NO CHARITABLE DONATIONS. The company incentivizes employees through pre-IPO...Show More

Alphamab Oncology announced in its annual report ending December 31, 2023, focuses on bi-specific antibody and protein engineering with the aim of promoting innovative biopharmaceuticals globally. The product pipeline includes tumor monoclonal antibodies, binospecific antibodies, and ADCs, of which one product has been approved and the other three are in the post-clinical stage. The company's first commercialized product is KN035 (Envafolimab), but commercialization experience is limited. The financial summary showed that total revenue reached RMB218.8 million, an increase over the previous year, with a net loss of RMB210.6 million, a decrease in the loss margin compared to last year. DURING THE REPORTING PERIOD, THE COMPANY DID NOT PROPOSE TO DISTRIBUTE DIVIDENDS AND NO CHARITABLE DONATIONS. The company incentivizes employees through pre-IPO and post-IPO stock option programs and adheres to relevant corporate governance codes, except that the roles of Chairman and CEO are not separated. DURING THE REPORTING PERIOD, THE COMPANY DID NOT ISSUE CONVERTIBLE BONDS OR WARRANTS. The shares are listed on the main board of the Hong Kong Stock Exchange. As of the last effective date, approximately 4.84% of the issued shares are available for post-IPO stock option plans. During the reporting period, 1,350,000 stock options were granted, 880,000 stock options expired and no stock options were canceled. In addition, the company has adopted a post-IPO limited stock reward program, similar to the objectives of the stock options program. DURING THE REPORTING PERIOD, THE COMPANY AND ITS SUBSIDIARIES DID NOT ENTER INTO SIGNIFICANT CONTRACTS WITH THE CONTROLLING SHAREHOLDERS OR THEIR SUBSIDIARIES, NOR DID THE COMPANY AND ITS SUBSIDIARIES PURCHASE, SELL OR REDEEM ANY LISTED SECURITIES, AND AS OF DECEMBER 31, 2023, THE COMPANY WAS NOT INVOLVED IN ANY MAJOR LITIGATION OR ARBITRATION, AND NO SIGNIFICANT LITIGATION OR CLAIMS WERE SETTLED.